安圖生物(603658.SH)擬定增募資不超32.8億元 用於體外診斷產業園(三期)項目等
格隆匯 6 月 15日丨安圖生物(603658.SH)披露2020年非公開發行股票預案,擬非公開發行股票數量按照此次非公開發行募集資金總額除以最終詢價確定的發行價格計算得出,且此次發行數量不超過此次非公開發行前公司總股本的10%,並以中國證監會關於此次發行的核準文件為準。
截至預案公告日,上市公司總股本為430,602,899股,按此計算,此次非公開發行股票數量不超過4306.0289萬(含本數)股。
募集資金總額不超過32.8億元,將投向安圖生物體外診斷產業園(三期)項目、安圖生物診斷儀器產業園之營銷網絡建設項目以及補充流動資金項目,用於做大做強公司現有主業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.